Ian McGowan

Summary

Affiliation: University of Pittsburgh
Country: USA

Publications

  1. ncbi Characterization of baseline intestinal mucosal indices of injury and inflammation in men for use in rectal microbicide trials (HIV Prevention Trials Network-056)
    Ian McGowan
    Center for Prevention Research in the Division of Digestive Diseases, Department of Medicine, David Geffen School of Medicine, University of Clifornia, Los Angeles, Los Angeles, CA, USA
    J Acquir Immune Defic Syndr 46:417-25. 2007
  2. ncbi Lack of decay of HIV-1 in gut-associated lymphoid tissue reservoirs in maximally suppressed individuals
    Michael A Poles
    Center for Prevention Research at David Geffen School of Medicine, University of California-Los Angeles AIDS Institute, University of California-Los Angeles, Los Angeles, CA 90095, USA
    J Acquir Immune Defic Syndr 43:65-8. 2006
  3. ncbi Binding and transfer of human immunodeficiency virus by DC-SIGN+ cells in human rectal mucosa
    Kevin B Gurney
    Dept. of Medicine, Division of Digestive Diseases, David Geffen School of Medicine at UCLA, 2734 MRL, 675 Charles E. Young Dr. South, Los Angeles, CA 90095-7019, USA
    J Virol 79:5762-73. 2005
  4. ncbi First phase 1 double-blind, placebo-controlled, randomized rectal microbicide trial using UC781 gel with a novel index of ex vivo efficacy
    Peter A Anton
    Center for HIV Prevention Research, UCLA AIDS Institute, Department of Medicine, David Geffen School of Medicine at the University of California Los Angeles, Los Angeles, California, United States of America
    PLoS ONE 6:e23243. 2011
  5. ncbi Increased HIV-1 mucosal replication is associated with generalized mucosal cytokine activation
    Ian McGowan
    Center for HIV and Digestive Diseases, Division of Digestive Diseases, University of California at Los Angeles AIDS Institute, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095, USA
    J Acquir Immune Defic Syndr 37:1228-36. 2004
  6. ncbi Microbicides: a new frontier in HIV prevention
    Ian McGowan
    Center for Prevention Research, David Geffen School of Medicine at UCLA, Los Angeles, 10940 Wilshire Boulevard, Suite 1250, Los Angeles, CA 90025, USA
    Biologicals 34:241-55. 2006
  7. ncbi Rectal microbicides
    Ian McGowan
    aUniversity of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA bDavid Geffen School of Medicine, University of California Los Angeles, Los Angeles, California, USA
    Curr Opin HIV AIDS 3:593-8. 2008
  8. ncbi Rectal microbicides: can we make them and will people use them?
    Ian McGowan
    Department of Medicine, Division of Gastroenterology, Haepatology, and Nutrition, University of Pittsburgh School of Medicine, 204 Craft Ave, Room B505, Pittsburgh, PA 15213, USA
    AIDS Behav 15:S66-71. 2011
  9. ncbi HIV-1 pathogenesis differs in rectosigmoid and tonsillar tissues infected ex vivo with CCR5- and CXCR4-tropic HIV-1
    Jean Charles Grivel
    National Institute of Child Health and Human Development, National Institutes of Health, 10 Center Drive, Bethesda, MD 20892, USA
    AIDS 21:1263-72. 2007

Collaborators

Detail Information

Publications9

  1. ncbi Characterization of baseline intestinal mucosal indices of injury and inflammation in men for use in rectal microbicide trials (HIV Prevention Trials Network-056)
    Ian McGowan
    Center for Prevention Research in the Division of Digestive Diseases, Department of Medicine, David Geffen School of Medicine, University of Clifornia, Los Angeles, Los Angeles, CA, USA
    J Acquir Immune Defic Syndr 46:417-25. 2007
    ..The purpose of this study was to evaluate the biologic stability of mucosal parameters that might be used as endpoints in phase 1 rectal safety studies...
  2. ncbi Lack of decay of HIV-1 in gut-associated lymphoid tissue reservoirs in maximally suppressed individuals
    Michael A Poles
    Center for Prevention Research at David Geffen School of Medicine, University of California-Los Angeles AIDS Institute, University of California-Los Angeles, Los Angeles, CA 90095, USA
    J Acquir Immune Defic Syndr 43:65-8. 2006
    ..In well-suppressed patients on highly active antiretroviral therapy, the GALT compartment showed no clear pattern of HIV-1 decay, similar to that in the PBMCs...
  3. ncbi Binding and transfer of human immunodeficiency virus by DC-SIGN+ cells in human rectal mucosa
    Kevin B Gurney
    Dept. of Medicine, Division of Digestive Diseases, David Geffen School of Medicine at UCLA, 2734 MRL, 675 Charles E. Young Dr. South, Los Angeles, CA 90095-7019, USA
    J Virol 79:5762-73. 2005
    ..DC-SIGN and the IL-10/IL-12 axis may play significant roles in the mucosal transmission and pathogenesis of HIV type 1...
  4. ncbi First phase 1 double-blind, placebo-controlled, randomized rectal microbicide trial using UC781 gel with a novel index of ex vivo efficacy
    Peter A Anton
    Center for HIV Prevention Research, UCLA AIDS Institute, Department of Medicine, David Geffen School of Medicine at the University of California Los Angeles, Los Angeles, California, United States of America
    PLoS ONE 6:e23243. 2011
    ..A first-in-Phase 1 assessment of preliminary pharmacodynamics was included by measuring changes in ex vivo HIV-1 suppression in rectal biopsy tissue after exposure to product in vivo...
  5. ncbi Increased HIV-1 mucosal replication is associated with generalized mucosal cytokine activation
    Ian McGowan
    Center for HIV and Digestive Diseases, Division of Digestive Diseases, University of California at Los Angeles AIDS Institute, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095, USA
    J Acquir Immune Defic Syndr 37:1228-36. 2004
    ..The pathologic basis for these observations is unclear but may relate to the success or failure of antiretroviral therapy in controlling mucosal viral replication...
  6. ncbi Microbicides: a new frontier in HIV prevention
    Ian McGowan
    Center for Prevention Research, David Geffen School of Medicine at UCLA, Los Angeles, 10940 Wilshire Boulevard, Suite 1250, Los Angeles, CA 90025, USA
    Biologicals 34:241-55. 2006
    ..The purpose of this article is to provide an overview of microbicide development and an update on the candidate pipeline...
  7. ncbi Rectal microbicides
    Ian McGowan
    aUniversity of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA bDavid Geffen School of Medicine, University of California Los Angeles, Los Angeles, California, USA
    Curr Opin HIV AIDS 3:593-8. 2008
    ..In addition, there is increasing awareness of the need to develop rectal specific microbicide formulations...
  8. ncbi Rectal microbicides: can we make them and will people use them?
    Ian McGowan
    Department of Medicine, Division of Gastroenterology, Haepatology, and Nutrition, University of Pittsburgh School of Medicine, 204 Craft Ave, Room B505, Pittsburgh, PA 15213, USA
    AIDS Behav 15:S66-71. 2011
    ..The purpose of this article is to describe the challenges and progress in the development of rectal microbicides for HIV prevention...
  9. ncbi HIV-1 pathogenesis differs in rectosigmoid and tonsillar tissues infected ex vivo with CCR5- and CXCR4-tropic HIV-1
    Jean Charles Grivel
    National Institute of Child Health and Human Development, National Institutes of Health, 10 Center Drive, Bethesda, MD 20892, USA
    AIDS 21:1263-72. 2007
    ....